Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
Rhea-AI Summary
Glucotrack (Nasdaq: GCTK) announced a peer‑reviewed publication in IEEE Sensors Journal (published April 7, 2026) reporting the first year‑long in‑vitro measurement of glucose oxidase deactivation in electrochemical sensors.
The study, done with TTP (UK), examined sensors built to mimic ~two‑year‑old devices and supports the feasibility of long‑life implantable continuous blood glucose monitoring. Glucotrack cited prior first‑in‑human results (MARD 7.7%, 99% data capture) and said the work supports near‑term IDE submission efforts.
AI-generated analysis. Not financial advice.
Positive
- Peer‑reviewed publication in IEEE Sensors Journal (April 7, 2026)
- First year‑long in‑vitro measurement of glucose oxidase deactivation reported
- Study partnered with TTP, a UK scientific and engineering organization
- Previous human data: MARD 7.7% and 99% data capture with no serious adverse events
Negative
- Study was in‑vitro rather than a new in‑human clinical trial
- IDE not yet submitted; company is working toward submission in the near term
News Market Reaction – GCTK
On the day this news was published, GCTK declined 3.97%, reflecting a moderate negative market reaction. Argus tracked a peak move of +25.4% during that session. Argus tracked a trough of -13.8% from its starting point during tracking. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $83K from the company's valuation, bringing the market cap to $2.00M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GCTK was down 2.38% while sector peers showed mixed moves: EKSO +6.95%, FEMY +1.05%, LUCY -2.73%, MHUA -27.18%, HBIO +15.35%. Momentum data show 4 peers trending down and 1 up, indicating stock-specific factors rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Earnings & update | Positive | -14.1% | Reported 2025 results, cash of $7.4M, and IDE plan for Q2 2026. |
| Mar 27 | IDE trial plans | Positive | -9.2% | Outlined IDE filing in Q2 2026 and U.S. trial start in H2 2026. |
| Mar 10 | Conference appearance | Neutral | -2.4% | Announced LSI USA ’26 presentation on CBGM technology and plans. |
| Jan 29 | Patent issuances | Positive | -33.4% | Announced three USPTO patents covering CBGM chemistry and hardware. |
| Dec 30 | Private placement | Negative | -10.8% | Priced $4.0M private placement with shares and 2,067,182 warrants. |
Recent history shows shares often selling off on otherwise constructive clinical, patent, and financing updates.
Over the last six months, Glucotrack has advanced its fully implantable CBGM platform through patents, first‑in‑human data, and financing. In Dec 2025, it priced a $4.0 million private placement. In Jan 2026, it highlighted three U.S. patents supporting multi‑year longevity. March updates covered conference visibility, an IDE filing plan for Q2 2026, and full‑year 2025 results with a $19.4M net loss. Despite largely positive operational milestones, share reactions to these news items were mostly negative, framing today’s technical publication against a backdrop of investor skepticism.
Regulatory & Risk Context
An effective S-3 filed on Jan 13, 2026 registers 3,224,803 common shares for resale by holders of pre‑funded, common, and placement agent warrants from the December 2025 private placement. The registered shares equal about 354% of shares outstanding as of January 12, 2026, indicating substantial potential dilution and stock overhang, even though Glucotrack itself will not receive proceeds from these resales.
Market Pulse Summary
This announcement reinforces the technical underpinnings of Glucotrack’s fully implantable CBGM by adding a year‑long glucose oxidase stability study to earlier first‑in‑human data showing MARD of 7.7% and 99% data capture. Historically, the company paired such milestones with capital raises and an effective S-3 registering 3,224,803 resale shares, alongside a $19.4M 2025 net loss and going‑concern language. Investors may watch future IDE submission timing, clinical results, and potential use of registered shares as key signals.
Key Terms
in-vitro medical
electrochemical glucose sensors medical
glucose oxidase medical
continuous blood glucose monitoring medical
cbgm medical
investigational device exemption regulatory
ide regulatory
mean absolute relative difference medical
AI-generated analysis. Not financial advice.
Year-long in-vitro characterization of glucose oxidase stability supports the feasibility of long-life implantable continuous glucose monitors, independent third party review of the longevity and functionality of design in the latter stage of in-human use
RUTHERFORD, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer-reviewed scientific article in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal characterizing the long-term in-vitro stability of electrochemical glucose sensors of the type used in the Company’s fully implantable continuous blood glucose monitoring (CBGM) system. The findings represent the first year-long measurement of glucose oxidase enzyme decay reported in the literature and support the feasibility of long-life implantable continuous glucose monitors.
The publication, titled “Year-Long Measurement of Glucose Oxidase Deactivation in Electrochemical Glucose Sensors,” (Ernst, S. et al.), examined the long-term in-vitro performance and stability of an electrochemical glucose sensor based on glucose oxidase, the enzyme class used in Glucotrack’s CBGM, over a one-year period.
The objective of the study was to assess sensor performance during the final year of its intended functional life. Accordingly, sensors used in the study were constructed to reflect approximately two year old devices. The findings represent the first year-long measurement of glucose oxidase enzyme decay, providing higher-confidence in the design of our long-life implantable glucose sensor.
Glucotrack partnered with TTP, a United Kingdom‑based scientific and engineering organization with experience supporting life sciences and medical device innovation, for this study and publication. The article was published on April 7, 2026 in the highly regarded technical journal, the IEEE Sensors Journal, part of the Institute of Electrical and Electronics Engineers, a global organization of over 486,000 leading STEM professionals worldwide, and is available online here.
“This work provides externally reviewed scientific evidence relevant to the design of long-life implantable glucose sensors. Peer-reviewed characterization of foundational sensor data is an important step as we continue to advance our development program and work toward clinical and regulatory milestones,” commented Dr. Paul Goode, President and Chief Executive Officer of Glucotrack.
“TTP has a strong reputation in our space, and we had a very positive experience working with their team. We anticipate that this article, among other similar projects we have in process, should serve our team well as we work towards the submission of our IDE with the FDA in the near term,” concluded Dr. Goode.
This publication is one part of Glucotrack’s ongoing effort to build a transparent, peer-reviewed technical foundation for the development of its CBGM technology. Glucotrack previously reported first-in-human clinical results demonstrating a highly-accurate MARD of
For more information about Glucotrack's CBGM, visit www.glucotrack.com.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.
| Contacts: | |
| Investor Relations: | Media: |
| investors@glucotrack.com | GlucotrackPR@icrinc.com |
